[go: up one dir, main page]

AR054045A1 - Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista - Google Patents

Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista

Info

Publication number
AR054045A1
AR054045A1 ARP060102018A ARP060102018A AR054045A1 AR 054045 A1 AR054045 A1 AR 054045A1 AR P060102018 A ARP060102018 A AR P060102018A AR P060102018 A ARP060102018 A AR P060102018A AR 054045 A1 AR054045 A1 AR 054045A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
heterocyclyl
alkyl
substituted
agioist
Prior art date
Application number
ARP060102018A
Other languages
English (en)
Original Assignee
Neuraxon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37727686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054045(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuraxon Inc filed Critical Neuraxon Inc
Publication of AR054045A1 publication Critical patent/AR054045A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuestos de la formula (1) o una de sus sales o profármacos farmacéuticamente aceptables, caracterizado porque, R1 es alquilo C1-6 opcionalmente sustituido, alcarilo C1-4 opcionalmente sustituido o alqheterociclilo C1- 4opcionalmente sustituido, arilo C6-10 opcionalmente sustituido, heterociclilo C2-9 en puente opcionalmente sustituido, alqheterociclilo C1-4 en puente opcionalmente sustituido, heterociclilo C2-9 opcionalmente sustituido, o alqheterociclilo C1-4 opcionalmente sustituido; cada uno de R3 y R4 es independientemente, H; F, alquilo C1-6 o alcoxi C1-6; R5 es H, R5AC(NH)NH(CH2)r5, R5ANHC(NH)NH(CH2)r5, o R5ANHC(NH(CH2)r5, donde r5 es un entero de 0 a 2 y R5A es alquilo C1-6 opcionalmente sustituido, arilo C6-10 opcionalmente sustituido, alcarilo C1-4 opcionalmente sustituido, heterociclilo C2-9 opcionalmente sustituido, alqheterociclilo C1-4, opcionalmente sustituido, tioalcoxi C1-6 opcionalmente sustituido, C1-4 opcionalmente sustituido, ariloílo opcionalmente sustituido; o nitro; y R6 es H, R6AC(NH)NH(CH2)r6, R6ANHC(NH)NH(CH2)r6, o R6ANHC(S)NH(CH2)r6, donde r6 es un entero de 0 a 2 y R6A es alquilo C1-6 opcionalmente sustituido, arilo C6-10 opcionalmente sustituido, heterociclilo C2-9 opcionalmente sustituido, alqheterociclilo C1-4 opcionalmente sustituido, tioalcoxi C1-6 opcionalmente sustituido, tioalcarilo C1-4 opcionalmente sustituido, ariloílo opcionalmente sustituido, tioalqheterociclilo C1-4 opcionalmente sustituido, o nitro; donde solo uno y no ambos de R5 y R6 es H. Composiciones farmacéuticas que los contienen y usos para tratar o prevenir el dolor cronico, agudo, migrana y dolor neuropático.
ARP060102018A 2005-05-18 2006-05-18 Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista AR054045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68204305P 2005-05-18 2005-05-18

Publications (1)

Publication Number Publication Date
AR054045A1 true AR054045A1 (es) 2007-05-30

Family

ID=37727686

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102018A AR054045A1 (es) 2005-05-18 2006-05-18 Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista

Country Status (8)

Country Link
US (1) US7919510B2 (es)
EP (1) EP1888568A4 (es)
JP (1) JP2008540638A (es)
AR (1) AR054045A1 (es)
AU (1) AU2006277684A1 (es)
CA (1) CA2607219A1 (es)
TW (1) TW200722084A (es)
WO (1) WO2007017764A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200846003A (en) * 2007-03-15 2008-12-01 Astellas Pharma Inc Novel prophylactic and/or therapeutic agent for diabetic neuropathy
TW200846002A (en) * 2007-03-15 2008-12-01 Astellas Pharma Inc Novel prophylactic and/or therapeutic agent for diabetic neuropathy
TWI417099B (zh) * 2007-03-23 2013-12-01 Neuraxon Inc 具抑制一氧化氮合成酶活性之喹諾酮、四氫喹啉及其相關化合物
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
UA105182C2 (ru) * 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
CN102149386A (zh) * 2008-09-11 2011-08-10 安斯泰来制药株式会社 伤害感受性疼痛的新型治疗用药物组合物
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
RU2475479C1 (ru) * 2011-12-23 2013-02-20 Федеральное государственное бюджетное учреждение Министерства здравоохранения и социального развития Российской Федерации "Медицинский радиологический научный центр" (ФГБУ МРНЦ Минздравсоцразвития России) Вазоконстрикторное средство
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3432884A4 (en) * 2016-03-22 2019-11-20 Regents of the University of Minnesota COMBINATIONS FOR THE TREATMENT OF PAIN
JP6980694B2 (ja) * 2016-04-13 2021-12-15 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法
BR112020018933A2 (pt) 2018-03-19 2020-12-29 Knopp Biosciences Llc Composto, composição farmacêutica, método de tratamento de um transtorno associado a kv7 e método de tratamento de um transtorno associado a uma mutação kcnq2
WO2025257786A1 (en) * 2024-06-13 2025-12-18 Iama Therapeutics S.R.L. Benzoimidazole derivatives as nkcc1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2935514A (en) * 1960-05-03 Benzimidazoles
DD123466A1 (es) 1975-12-01 1976-12-20
US4879295A (en) 1986-09-27 1989-11-07 Sawai Pharmaceutical Co., Ltd. N-tetrazolyl thiazolecarboxyamide derivatives and their use
JPH09505029A (ja) 1993-07-19 1997-05-20 藤沢薬品工業株式会社 ドパミン受容体作動薬、５−ＨＴ受容体拮抗薬あるいはα▲下１▼受容体拮抗薬として有用なベンズイミダゾール誘導体
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
JPH10265450A (ja) * 1997-03-25 1998-10-06 Mitsui Chem Inc 一酸化窒素合成酵素阻害作用を有する新規なアミジン誘導体
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7132438B2 (en) * 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
ITTO20040125A1 (it) * 2004-03-01 2004-06-01 Rotta Research Lab Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica
GB0510151D0 (en) * 2005-05-18 2005-06-22 Syngenta Ltd Novel herbicides
ES2351228T3 (es) * 2005-05-18 2011-02-01 Basf Se Anilidas de ácidos tiazolcarboxílicos.

Also Published As

Publication number Publication date
AU2006277684A1 (en) 2007-02-15
WO2007017764A2 (en) 2007-02-15
US20080214613A1 (en) 2008-09-04
JP2008540638A (ja) 2008-11-20
US7919510B2 (en) 2011-04-05
EP1888568A2 (en) 2008-02-20
WO2007017764A3 (en) 2007-07-05
CA2607219A1 (en) 2007-02-15
EP1888568A4 (en) 2009-08-12
TW200722084A (en) 2007-06-16

Similar Documents

Publication Publication Date Title
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
AR054045A1 (es) Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR042273A1 (es) Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen
AR060451A1 (es) Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
AR042658A1 (es) Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
NI200900021A (es) Inhibidor de quinasa
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
EA200900279A1 (ru) Арилсульфонамиды с аналгетическим действием
AR054184A1 (es) Derivados de 1,5 difenilpirazol. procesos de obtencion y composiciones farmaceuticas.
AR047898A1 (es) Benzamidas sustituidas,metodos de preparacion,composiciones farmaceuticas que las contienen y usos
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR053149A1 (es) Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
AR074604A1 (es) Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
AR049712A1 (es) DERIVADOS DE PIRIMIDINA COMO INHIBIDORES DE PI3K; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO CON EFECTO ANTI-PROLIFERATIVO.
AR049385A1 (es) Sulfoniletil fosforodiamidatos

Legal Events

Date Code Title Description
FB Suspension of granting procedure